GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Frontage Holdings Corp (HKSE:01521) » Definitions » Total Liabilities

Frontage Holdings (HKSE:01521) Total Liabilities : HK$1,771 Mil (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Frontage Holdings Total Liabilities?

Frontage Holdings's Total Liabilities for the quarter that ended in Dec. 2023 was HK$1,771 Mil.

Frontage Holdings's quarterly Total Liabilities declined from Dec. 2022 (HK$1,671.88 Mil) to Jun. 2023 (HK$1,551.63 Mil) but then increased from Jun. 2023 (HK$1,551.63 Mil) to Dec. 2023 (HK$1,770.65 Mil).

Frontage Holdings's annual Total Liabilities increased from Dec. 2021 (HK$1,191.36 Mil) to Dec. 2022 (HK$1,671.88 Mil) and increased from Dec. 2022 (HK$1,671.88 Mil) to Dec. 2023 (HK$1,770.65 Mil).


Frontage Holdings Total Liabilities Historical Data

The historical data trend for Frontage Holdings's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Frontage Holdings Total Liabilities Chart

Frontage Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Liabilities
Get a 7-Day Free Trial 390.15 727.45 1,191.36 1,671.88 1,770.65

Frontage Holdings Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,191.36 1,294.35 1,671.88 1,551.63 1,770.65

Frontage Holdings Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Frontage Holdings's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=777.7+(884.757+108.196
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=1,771

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=4466.183-2695.529
=1,771

Frontage Holdings's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=777.7+(884.757+108.196
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=1,771

Total Liabilities=Total Assets (Q: Dec. 2023 )-Total Equity (Q: Dec. 2023 )
=4466.183-2695.529
=1,771

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Frontage Holdings Total Liabilities Related Terms

Thank you for viewing the detailed overview of Frontage Holdings's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Frontage Holdings (HKSE:01521) Business Description

Traded in Other Exchanges
Address
700 Pennsylvania Drive, Exton, PA, USA, 19341
Frontage Holdings Corp is a contract research organization providing integrated, scientifically driven research, analytical and development services. Geographically the group operates in both PRC and North America. The services provided in the North American segment, include Bioanalytical, CMC, DMPK and Safety and Toxicology services in the USA and Canada. The service offered in PRC includes Bioanalytical, Bioequivalence and CMC services in the PRC. Further, it also provides bioanalytical services, which are offered throughout the drug discovery and development process both in the United States and China.

Frontage Holdings (HKSE:01521) Headlines

No Headlines